Visão geral da empresa
A biotechnology enterprise, Tiziana Life Sciences Ltd specializes in the development of transformative therapies targeting neurodegenerative and lung diseases within the United States market. The company operates within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory hurdles before products reach commercialization. The total market capitalization stands at $161.60M, while the reported annual revenue is N/A, and the organization employs 9 individuals. The valuation figure of $161.60M, combined with the absence of reported revenue data, indicates that the company is likely in a pre-revenue or early-stage clinical development phase where value is derived entirely from intellectual property and pipeline potential rather than current cash generation. The minimal employee count of 9 suggests a highly lean operational structure typical of early-stage biotech firms that rely on external partnerships and grant funding to mitigate overhead costs. Consequently, the financial scale reflects a capital-intensive business model where current assets are heavily weighted towards intangible assets like patents rather than physical infrastructure or large sales teams.
Saúde financeira
The financial statements for the trailing twelve months show revenue as N/A, a net income loss of $-12,841,000, and an EBITDA figure of $-18,464,000. The substantial gap between the reported revenue figure of N/A and the significant net income loss of $-12,841,000 reveals a cost structure dominated by research and development expenses, administrative overhead, and clinical trial costs that far exceed any current sales activity. Free cash flow stands at $-3,856,625, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from business activities. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are listed as 0.0%, a metric that signifies the company has not yet achieved positive profitability from its sales, as no revenue has been generated to calculate a meaningful margin percentage. The balance sheet shows a cash position of $7.25M against total debt of $107,000, resulting in a debt-to-equity ratio of 1.16 which suggests a leveraged financial structure despite the low absolute debt amount. The current ratio of 1.72 indicates that the company holds sufficient current assets to cover its short-term liabilities, providing a moderate buffer for liquidity management. Return on Equity is reported at -232.3% and Return on Assets is -83.8%, metrics that reveal management is currently not generating positive returns on the capital invested or the assets employed, which is expected for a company with zero revenue but high burn rates.
Avaliação de valorização
The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -6.48, implying that earnings are currently negative and the market is pricing the stock based on future expectations of turning those losses into profits. The price-to-book ratio is 16.49, indicating that the market values the company at a significant premium of 16.49 times its net book value, a common characteristic for biotech firms where assets are primarily intellectual property not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio are N/A due to lack of revenue, while the EV/EBITDA stands at -7.79, suggesting the valuation is heavily dependent on the perceived value of the drug pipeline rather than traditional earnings multiples. The stock has traded between a 52-week low of $0.73 and a 52-week high of $2.60, meaning the current price sits at a specific point within this range relative to the volatility observed over the past year. The beta value of 0.37 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market movements but carries specific idiosyncratic risks related to its clinical trials.
Growth & Income
The reported revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, preventing a direct comparison of earnings growth versus revenue growth since no revenue baseline exists. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the organization reinvests all available resources and capital into research, development, and operational expansion rather than distributing income to shareholders. The absence of a dividend yield implies that shareholder returns are exclusively capital appreciation driven by the success of the Foralumab candidate and other pipeline assets. The overall growth and income profile is currently defined by a reliance on non-dilutive funding or equity financing to sustain negative growth metrics until revenue generation begins.